A groundbreaking clinical trial led by Dr. Zev Wainberg at UCLA Health has shown that a new drug, daraxonrasib, can significantly extend the lives of patients with advanced pancreatic cancer. This promising development was presented at the American Society of Clinical Oncology’s annual meeting in Chicago, highlighting the drug’s potential to double survival times compared to traditional chemotherapy.
Hope for Pancreatic Cancer Patients
Pancreatic cancer, known for its grim prognosis, often leaves patients with limited options. Daraxonrasib, however, has demonstrated remarkable results in a phase 3 trial involving 500 patients, extending average survival from 6.7 months with chemotherapy to 13.2 months. This has sparked hope among oncologists and patients alike, as the drug targets a mutation in the KRAS gene, prevalent in over 90% of pancreatic cancers.
Dr. Rachna Shroff from the University of Arizona Cancer Center expressed her excitement, calling the drug a ‘game-changer’ for treating pancreatic cancer. The FDA has fast-tracked daraxonrasib for approval, and Revolution Medicines, the drug’s manufacturer, is working tirelessly to make it available to more patients through an expanded access program.
Beyond Pancreatic Cancer
Daraxonrasib’s potential extends beyond pancreatic cancer. The drug targets the KRAS mutation found in various cancers, including lung, colorectal, and ovarian cancers. Dr. Brian Wolpin from Dana-Farber Cancer Institute believes this is just the beginning, with the drug opening ‘floodgates’ for treating other cancers.
While daraxonrasib is not a cure, it offers a less toxic alternative to chemotherapy, with manageable side effects such as mild rashes and mouth sores. Patients like Debby Orcutt, who saw significant tumor reduction, are living proof of its impact. Orcutt, a 71-year-old from Spencer, Massachusetts, continues to lead an active life, crediting the drug for her improved health.
As research continues, oncologists are hopeful that daraxonrasib will become a staple in cancer treatment, providing patients with more time and better quality of life.
Original reporting: NBC10 Boston — read the source article.
